GOG GYN-LIVE - INDUSTRY SUPPORTED SYMPOSIA

The GOG Foundation, Inc
  • 0.0 (0)
  • Medicine

The GOG Foundation, Inc. and GOG Partners are thrilled to share enduring education from Industry Supported Symposia that showcases clinical trials and other newsworthy education, from major medical meetings throughout the year.

Episodes

  1. Precision in Endometrial Cancer: Personalized Treatment Strategies for pMMR and dMMR Endometrial Cancer: Charting the Course: Treatment Approaches for dMMR Endometrial Cancer

    May 29

    Precision in Endometrial Cancer: Personalized Treatment Strategies for pMMR and dMMR Endometrial Cancer: Charting the Course: Treatment Approaches for dMMR Endometrial Cancer

    This interactive 90-minute symposium will explore the evolving treatment landscape in endometrial cancer, focusing on the distinctions between dMMR and pMMR disease. Faculty will provide expert insights on current treatment paradigms, including immunotherapy, chemotherapy, and novel combinations. Through integrated patient case discussions, the session will highlight how molecular profiling drives treatment selection, the importance of toxicity management, and strategies for sequencing therapies across patient subtypes. The session will conclude with forward-looking perspectives on addressing data gaps and improving outcomes.

    19 min
  2. Evidence Based Biomarker-Driven Advances in Ovarian & Endometrial Cancer: Equitable, Individualized and Accessible Care

    Feb 9

    Evidence Based Biomarker-Driven Advances in Ovarian & Endometrial Cancer: Equitable, Individualized and Accessible Care

    This course offers a clinically relevant exploration of evolving treatment strategies in ovarian and endometrial cancers for a global audience.  The primary focus of this course will help learners understand how to make biomarker-driven decisions for on-label therapeutic pathways. Learners will deepen their understanding of the role of BRCA, HRD, MMR/MSI, and emerging biomarkers such as p53 for equitable and individualized care treatment plans that aim to improve patient outcomes.   Through cased-based learning, the program emphasizes the real-world application of molecular testing, including how to interpret biomarker results and integrate them into treatment.  Key trials such as SOLO-1, PAOLA-1, PRIMA, DUO-E and ARIEL3 will be discussed to illustrate evidence-based approaches to selecting the right therapy for the right patient, particularly in the context of PARP inhibitor use and HRD testing as well as target based ADCs.  The course acknowledges geographic disparities, particularly in areas with limited on-the-ground support and aims to provide practical guidance for clinicians who are working to implement testing and treatment strategies under local constraints.  Additionally, the program will explore emerging therapeutic targets and biomarkers, including the potential of antibody-drug conjugates (ADCs), Her2 and Folate Receptor Alpha, and discuss how evolving science is reshaping treatment landscapes. Consideration will be given to health equity, access to testing, and the implementation challenges faced by clinicians and patients across diverse care environments.   All content will be aligned with current regulatory guidelines and appropriate for independent medical education (IME), with a clear distinction between on-label use and emerging data requiring further validation.

    1h 5m
  3. Precision in Endometrial Cancer: Personalized Treatment Strategies for pMMR and dMMR Endometrial Cancer First Installment

    Feb 9

    Precision in Endometrial Cancer: Personalized Treatment Strategies for pMMR and dMMR Endometrial Cancer First Installment

    This interactive 90-minute symposium will explore the evolving treatment landscape in endometrial cancer, focusing on the distinctions between dMMR and pMMR disease. Faculty will provide expert insights on current treatment paradigms, including immunotherapy, chemotherapy, and novel combinations. Through integrated patient case discussions, the session will highlight how molecular profiling drives treatment selection, the importance of toxicity management, and strategies for sequencing therapies across patient subtypes. The session will conclude with forward-looking perspectives on addressing data gaps and improving outcomes.

    1h 27m
  4. Beyond the Image: New Opportunities in Gynecologic Cancer Testing

    Feb 9

    Beyond the Image: New Opportunities in Gynecologic Cancer Testing

    Minimal Residual Disease (MRD) testing using circulating tumor DNA (ctDNA) has emerged as a promising tool for improving the management of gynecologic malignancies, including endometrial, ovarian, and cervical cancers. This 90-minute course explores the evolving role of ctDNA in identifying disease recurrence and assessing treatment response—potentially earlier than imaging or traditional biomarkers.   Participants will receive an in-depth overview of the biological basis of ctDNA detection, the current clinical evidence supporting its utility, and its integration into clinical workflows. Case-based discussions will illustrate real-world applications, showcasing how ctDNA can optimize decisions on surveillance and therapeutic strategy. The program will also critically assess limitations and challenges of ctDNA-based MRD testing, including issues with sensitivity, false positives, access, and cost.   In alignment with a fair and balanced approach, the course will also explore other MRD detection modalities such as radiologic imaging, CA-125, and histopathology, highlighting comparative strengths and contexts for use. The program engages clinicians to learn how to interpret ctDNA MRD data and apply it effectively within a multidisciplinary care framework.

    1h 7m
  5. The Long Game in Endometrial Cancer: Interpreting PFS, OS, and the Power of Biomarkers

    Feb 9

    The Long Game in Endometrial Cancer: Interpreting PFS, OS, and the Power of Biomarkers

    This educational program offers a comprehensive and clinically relevant exploration of the rapidly evolving endometrial cancer treatment landscape, with a particular focus understanding the dynamic and evolving competitive landscape. The curriculum is designed to address the need for deeper clarity around differences in trial design, key efficacy outcomes, and therapeutic positioning.   Through a detailed review of data from recent clinical trials and study designs, participants will gain critical insights into progression-free and overall survival (PFS/OS) subgroup analyses, including those based on MMR status, HRD, IO, P53 mutation profiles, and other biologically relevant subgroups. Special emphasis will be placed on interpreting unplanned analyses, understanding the impact of FDA approvals, and evaluating gaps in existing content that may hinder clinical decision-making.  This program will incorporate emerging and established treatment options to help clinicians differentiate within a complex and competitive therapeutic landscape. Discussion will also highlight unmet needs, where treatment guidance remains less clear.   This fair and balanced program includes expert-led dialogue on how evolving data—both planned and exploratory—should be interpreted in practice and how these findings might reshape frontline and recurrent treatment strategies in endometrial cancer.

    1h 25m
  6. Global Perspective in Advanced, Recurrent Cervical Cancer: Resources, Opportunities and Access to Care.

    Feb 9

    Global Perspective in Advanced, Recurrent Cervical Cancer: Resources, Opportunities and Access to Care.

    This educational session explores the evolving global landscape of advanced and recurrent cervical cancer, with a focus on disparities in access to care and treatment innovations. Participants will review pivotal clinical trial data shaping current treatment paradigms, including the role of antibody-drug conjugates (ADCs) as a novel therapeutic option. Emphasis will be placed on how to compare and contrast global differences in treatment landscape and novel therapy implementation. Pearls for successful implementation of TV patient education, disease prevalence, and prevention strategies, with a spotlight on African regional statistics and global efforts to eliminate cervical cancer. The session will also highlight the World Health Organization’s approach to improving overall survival and discuss opportunities for healthcare professionals to contribute to global cervical cancer elimination initiatives.

    56 min
  7. From Data to Decisions: Evolving Opportunities in Platinum Resistant Ovarian Cancer

    Feb 9

    From Data to Decisions: Evolving Opportunities in Platinum Resistant Ovarian Cancer

    While antibody-drug conjugates (ADCs) have reshaped therapeutic paradigms, the latest clinical trial results reveal a broader array of opportunities, spanning novel mechanisms of action, immunotherapy-based combinations, and molecularly targeted strategies. Through rigorous analysis of newly presented efficacy and safety data, including key PFS/OS endpoints, expert faculty will provide context and interpretation to support real-world clinical decisions. Interactive discussion will center on how these innovations are poised to reshape treatment sequencing and improve patient outcomes. This dynamic symposium will spotlight the most compelling new data presented at 2025 oncology congresses, including ASCO, ESMO GYN, and ESMO—focusing on evolving strategies for the management of advanced, platinum-resistant high-grade epithelial ovarian cancer.

    1h 20m
  8. A New Era in Recurrent LGSOC: Incorporating Approved Therapies, Biomarkers, and Clinical Strategies

    Feb 9

    A New Era in Recurrent LGSOC: Incorporating Approved Therapies, Biomarkers, and Clinical Strategies

    This symposium will explore the rapidly evolving landscape of treatment for recurrent low-grade serous ovarian cancer (LGSOC), with a focus on newly FDA-approved therapies and investigational strategies, MEC Inhibitors, CDK46 Inhibitors, hormonal treatments and other opportunities in the competitive landscape. LGSOC remains a challenging subtype due to its unique biology and resistance to conventional therapies. Faculty will examine recent clinical trial data, discuss emerging best practices for biomarker testing and sequencing, and explore practical considerations for managing side effects and ensuring patient access to innovative treatments. Through real-world cases and interactive discussion, participants will gain insights to personalize care and optimize outcomes for patients living with recurrent LGSOC.

    1h 13m
  • 8 Episodes

About

The GOG Foundation, Inc. and GOG Partners are thrilled to share enduring education from Industry Supported Symposia that showcases clinical trials and other newsworthy education, from major medical meetings throughout the year.

Information

  • Creator
    The GOG Foundation, Inc
  • Years Active
    2K
  • Episodes
    8
  • Rating
    Clean
  • Copyright
    © 2026 The GOG Foundation, Inc